85 related articles for article (PubMed ID: 34102191)
21. The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia.
Demyanets S; Jaeger E; Pablik E; Greiner G; Herndlhofer S; Valent P; Schwarzinger I
Br J Haematol; 2018 Apr; 181(1):137-139. PubMed ID: 28220937
[No Abstract] [Full Text] [Related]
22. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
[TBL] [Abstract][Full Text] [Related]
23. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
Noori S; Nourbakhsh M; Farzaneh S; Zarghi A
Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949
[TBL] [Abstract][Full Text] [Related]
24. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
26. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
Mu C; Wu X; Ma H; Tao W; Zhang G; Xia X; Shen J; Mai J; Sun T; Sun X; Arlinghaus RB; Shen H
Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
28. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of brevilin A.
Su T; Wang YP; Wang XN; Li CY; Zhu PL; Huang YM; Yang ZY; Chen SB; Yu ZL
Life Sci; 2020 Jan; 241():117169. PubMed ID: 31843524
[TBL] [Abstract][Full Text] [Related]
29. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
[TBL] [Abstract][Full Text] [Related]
30. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
31. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
Ma AC; Fan A; Ward AC; Liongue C; Lewis RS; Cheng SH; Chan PK; Yip SF; Liang R; Leung AY
Exp Hematol; 2009 Dec; 37(12):1379-1386.e4. PubMed ID: 19772888
[TBL] [Abstract][Full Text] [Related]
32. Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway.
Liu JR; Wu WJ; Liu SX; Zuo LF; Wang Y; Yang JZ; Nan YM
Pathol Res Pract; 2015 Jun; 211(6):426-34. PubMed ID: 25724470
[TBL] [Abstract][Full Text] [Related]
33. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
34. Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer.
Zhu Z; Xiang Q; Li S; Chen C; Shi J
Biochem Pharmacol; 2024 Jul; 225():116268. PubMed ID: 38723720
[TBL] [Abstract][Full Text] [Related]
35. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.
Mukthavaram R; Ouyang X; Saklecha R; Jiang P; Nomura N; Pingle SC; Guo F; Makale M; Kesari S
J Transl Med; 2015 Aug; 13():269. PubMed ID: 26283544
[TBL] [Abstract][Full Text] [Related]
36. A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer.
Kim do Y; Park EY; Chang E; Kang HG; Koo Y; Lee EJ; Ko JY; Kong HK; Chun KH; Park JH
Oncotarget; 2016 Mar; 7(12):14791-802. PubMed ID: 26895471
[TBL] [Abstract][Full Text] [Related]
37. Circ-UBR1 facilitates proliferation, metastasis, and inhibits apoptosis in breast cancer by regulating the miR-1299/CCND1 axis.
Zhang L; Sun D; Zhang J; Tian Y
Life Sci; 2021 Feb; 266():118829. PubMed ID: 33259864
[TBL] [Abstract][Full Text] [Related]
38. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
39. Targeting Phosphorylation of Y-Box-Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance.
Shibata T; Watari K; Kawahara A; Sudo T; Hattori S; Murakami Y; Izumi H; Itou J; Toi M; Akiba J; Akagi Y; Tanaka M; Kuwano M; Ono M
Mol Cancer Ther; 2020 Mar; 19(3):882-894. PubMed ID: 31879363
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of long noncoding RNA TP73-AS1 suppresses the malignant progression of breast cancer cells in vitro through targeting miRNA-125a-3p/metadherin axis.
Liu Y; Wei G; Ma Q; Han Y
Thorac Cancer; 2020 Feb; 11(2):394-407. PubMed ID: 31901156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
